The Latest Cardiac and Vascular News
CARLSBAD, Calif., Nov. 12, 2020 (GLOBE NEWSWIRE) — Acutus Medical, Inc. (“Acutus”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today reported results for the third quarter of 2020. Recent Highlights: Reported revenue of $3.2 million in the third quarter ended September […]
ECHO Data from EXPLORER-HCM Show Mavacamten Treatment Improved Cardiac Structure and Mitral Valve Function in Obstructive Hypertrophic Cardiomyopathy Patients Markers of Physical Activity from MAVERICK-HCM Accelerometry Data Correlated with Markers of HCM Severity in Non-Obstructive HCM Non-Clinical Data Show Mavacamten Surrogate Preserved Cardiac Function in Disease Model, Slowing Progression BRISBANE, Calif., Nov. 13, 2020 (GLOBE NEWSWIRE) — MyoKardia, Inc. (Nasdaq: MYOK) today presented clinical […]
IRVINE, Calif., Nov. 13, 2020 (GLOBE NEWSWIRE) — Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, today announced follow-up results of the first 230 patients enrolled in its FLASH study. FLASH […]
Pooled data analyses from Phase III ORION-9, -10 and -11 showed that inclisiran consistently reduced low-density lipoprotein cholesterol (LDL-C) by approximately 51% in both male and female adult patients and in three age categories1,2 Sustained LDL-C reduction with inclisiran was observed regardless of age or gender differences1,2 with two doses a year, after an initial […]
– Treatment with sotatercept in the ongoing PULSAR Phase 2 trial was associated with improvements in cardiac and pulmonary function at week 24 – – Presentation of echocardiography data from the PULSAR trial received AHA’s “Cardiopulmonary Best Abstract” Award – – Preclinical research shows sotatercept inhibits cardiac remodeling, restores function […]
– ARO-APOC3 achieved triglyceride reductions of 74-92% – ARO-ANG3 achieved triglyceride reductions of 29-75% and LCL-C reductions of 29-35% – Company to host upcoming KOL webinars on ARO-APOC3 and ARO-ANG3 PASADENA, Calif.–(BUSINESS WIRE)–Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced positive clinical data from multiple product candidates in its cardiometabolic pipeline at the American […]
− Patients Receiving Investigational ALN-AGT Experienced Dose-Dependent Reductions in Blood Pressure, Confirming Potential for RNAi-Mediated Angiotensinogen (AGT) Silencing as a Novel Therapeutic Approach for Hypertension – − Durable AGT Knockdown Through 12 Weeks Supports a Once Quarterly or Potentially Less Frequent Dosing Regimen – − ALN-AGT Generally Well Tolerated, with […]
TRANSLATE-HF study establishes the potential for broad use of the only SGLT2 inhibitor indicated in patients with heart failure with reduced ejection fraction with and without diabetes WILMINGTON, Del.–(BUSINESS WIRE)–New data from a large, contemporary US hospitalized heart failure (HF) registry confirms that four out of five (81.1%) patients with […]
The new program will launch for members from Vida’s national payer customers in December of this year with a full rollout in January of 2021 SAN FRANCISCO–(BUSINESS WIRE)–Expanding on its commitment to improve health outcomes for millions of lives, Vida Health announced a new app-based, coach-centered virtual congestive heart failure (CHF) management […]
Expanded pivotal Phase 3 REVERSE-IT trial of product candidate bentracimab (PB2452) for reversal of antiplatelet effects of ticagrelor into Canada and dosed first patients outside the United States Resuming enrollment in ongoing Phase 2b trial of pemziviptadil (PB1046) in pulmonary arterial hypertension MALVERN, Pa. & SAN DIEGO–(BUSINESS WIRE)–PhaseBio Pharmaceuticals, Inc. (Nasdaq: […]
